Detailed information on the first facial transplantation procedure performed in the United States is presented in the January issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). The patient has recovered well, with no serious complications through eight months of follow-up. With “true dedication” to her recovery, the patient has regained most facial functions, and the ability to eat solid foods and drink from a cup.

For the full story, Click Here

A new study by Loyola University Health System researchers could lead to alternative treatments that would shrink skin cancer tumors with drugs. The drugs would work by turning on a gene that prevents skin cells from becoming cancerous. More than 1 million people in the United States are diagnosed with skin cancer each year. In the new study, researchers examined a type of skin cancer, called squamous cell carcinoma.

For the full story, Click Here

Pfizer Inc and Debiopharm Group™ have announced that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Debiopharm will assume responsibility for conducting the phase 3 trial of tremelimumab and Pfizer will retain responsibility for its worldwide commercialization.

For the full story, Click Here

Upwards of 76 percent of patients with chronic rhinosinusitis (CRS) experienced significant quality of life (QOL) improvements after undergoing endoscopic sinus surgery (ESS), according to new research in the January 2010 issue of Otolaryngology – Head and Neck Surgery. CRS is a debilitating form of sinusitis that can lead to significant physical symptoms as well as substantial functional and emotional impairment.

For the full story, Click Here